Abstract
Human population bears a similarity to an extent of 99.9%, however mere 0.1% of variability also creates large differences in personal make-up owing to several hereditary and environmental factors. Conventionally, development of healthcare modalities like diagnostics and therapeutics has been by mass production assuming uniformity in characteristics of recipient population. Due to the inherent variability in each individual clinical response to diagnostic and therapeutic products vary greatly ranging from inefficient therapeutic compliance, adverse reactions and hypersensitivity reactions. Personalization of medications is the need of hour to avoid perils of both modalities so that efficient healthcare is provided to human population. Advances in delivery like targeted drug formulations, companion diagnostics and triggered drug formulations provide necessary dimensions to personalized medicines. Formulations with these capabilities can be described as theranostics and have been instrumental in this decade to establish the field of personalized medicine. The current chapter reviews different types, mechanisms of targeted and triggered drug delivery systems that have helped to improve the diagnostic and therapeutic compliance in disease management.
References
Jain KK. Textbook of personalized medicine. 2nd ed. Berlin: Springer; 2015.
Personalized Medicine Coalition. 2015. http://www.personalizedmedicinecoalition.org/News/Press_Releases/More_Than_1_in_4_Novel_New_Drugs_Approved_by_FDA_in_2015_are_Personalized_Medicines. Accessed Sept 2017.
Reiss T. Drug discovery of the future: the implications of the human genome project. Trends Biotechnol. 2001;19(12):496–9. doi:10.1016/S0167-7799(01)01811-X.
Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol. 2001;19(12):491–6. doi:10.1016/S0167-7799(01)01814-5.
Doren M, Samsioe G. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1995. Hum Reprod Update. 2000;6(5):419–26.
Wening K, Breitkreutz J. Oral drug delivery in personalized medicine: unmet needs and novel approaches. Int J Pharm. 2011;404:1–9. doi:10.1016/j.ijpharm.2010.11.001.
Wang B, Zhuang X, Deng Z-B, Jiang H, Mu J, Wang Q, Xiang X, Guo H, Zhang L, Dryden G, Yan J, Miller D, Zhang H-G. Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from grapefruit. Mol Therapeutics. 2014;22(3):522–34. doi:10.1038/mt.2013.190.
Tiwari G, Tiwari R, Wal P, Wal A, Rai AK. Primary and novel approaches for colon targeted drug delivery—a review. Int J Drug Deliv. 2010;2:1–11.
Friend DR, Chang GW. A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J Med Chem. 1984;27(3):261–6. doi:10.1021/jm00369a005.
Hata T, Shimazaki Y, Kagayama A, Tamura S, Ueda S. Development of a novel drug delivery system, time-controlled explosion system (TES): V. Animal pharmacodynamic study and human bioavailability study. Int J Pharm. 1994;110(1):1–7. doi:10.1016/0378-5173(94)90369-7.
Tozaki H, Odoriba T, Okada N, Fujita T, Terabe A, Suzuki T, Okabe S, Muranishi S, Yamamoto A. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J Control Release. 2002;82(1):51–61. doi:10.1016/S0168-3659(02)00084-6.
Lu W, Tan Y-Z, K-L H, Jiang X-G. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood–brain barrier. Int J Pharm. 2005;295(1-2):247–60. doi:10.1016/j.ijpharm.2005.01.043.
Lu W, Wan J, Zhang Q, She Z, Jiang X. Aclarubicin-loaded cationic albumin-conjugated pegylated nanoparticle for glioma chemotherapy in rats. Int J Cancer. 2007;120(2):420–31. doi:10.1002/ijc.22296.
Qin Y, Chen H, Zhang Q, Wang X, Yuan W, Kuai R, Tang J, Zhang L, Zhang Z, Zhang Q, Liu J, He Q. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm. 2011;420(2):304–12. doi:10.1016/j.ijpharm.2011.09.008.
Fenart L, Casanova A, Dehouck B, Duhem C, Slupek S, Cecchelli R, Betbeder D. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther. 1999;291(3):1017–22.
Zhang P, Hu L, Yin Q, Zhang Z, Feng L, Li Y. Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation. J Control Release. 2012;159(3):429–34. doi:10.1016/j.jconrel.2012.01.031.
Huwyler JWD, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci. 1996;93:14164–9.
Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R, et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther. 2008;324:1064–72.
Sun X, Pang Z, Ye H, Qiu B, Guo L, Li J, Ren J, Qian Y, Zhang Q, Chen J, Jiang X. Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome. Biomaterials. 2012;33(3):916–24. doi:10.1016/j.biomaterials.2011.10.035.
Tamaru M, Akita H, Fujiwara T, Kajimoto K, Harashima H. Leptin-derived peptide, a targeting ligand for mouse brain-derived endothelial cells via macropinocytosis. Biochem Biophys Res Commun. 2010;394(3):587–92. doi:10.1016/j.bbrc.2010.03.024.
Lockman PR, Oyewumi MO, Koziara JM, Roder KE, Mumper RJ, Allen DD. Brain uptake of thiamine-coated nanoparticles. J Control Release. 2003;93(3):271–82. doi:10.1016/j.jconrel.2003.08.006.
Gaillard PJ, de Boer AG. 2B-trans™ technology: targeted drug delivery across the blood-brain barrier. In: Jain KK, editor. Drug delivery systems. Totowa, NJ: Humana Press; 2008. p. 161–75. doi:10.1007/978-1-59745-210-6_8.
Son YJ, Jang J-S, Cho YW, Chung H, Park R-W, Kwon IC, Kim I-S, Park JY, Seo SB, Park CR, Jeong SY. Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J Control Release. 2003;91(1-2):135–45. doi:10.1016/S0168-3659(03)00231-1.
Lee E, Lee J, Lee I-H, Yu M, Kim H, Chae SY, Jon S. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J Med Chem. 2008;51(20):6442–9. doi:10.1021/jm800767c.
Mody VV, Cox A, Shah S, Singh A, Bevins W, Parihar H. Magnetic nanoparticle drug delivery systems for targeting tumor. Appl Nanosci. 2013;4(4):385–92. doi:10.1007/s13204-013-0216-y.
Chen F-H, Zhang L-M, Chen Q-T, Zhang Y, Zhang Z-J. Synthesis of a novel magnetic drug delivery system composed of doxorubicin-conjugated Fe3O4 nanoparticle cores and a PEG-functionalized porous silica shell. Chem Commun. 2010;46(45):8633–5. doi:10.1039/C0CC02577A.
Arias JL, Gallardo V, Ruiz MA, Delgado ÁV. Magnetite/poly(alkylcyanoacrylate) (core/shell) nanoparticles as 5-fluorouracil delivery systems for active targeting. Eur J Pharm Biopharm. 2008;69(1):54–63. doi:10.1016/j.ejpb.2007.11.002.
Ogawara K-i, Yoshida M, Higaki K, Toshikiro K, Shiraishi K, Nishikawa M, Takakura Y, Hashida M. Hepatic uptake of polystyrene microspheres in rats: effect of particle size on intrahepatic distribution. J Control Release. 1999;59(1):15–22. doi:10.1016/S0168-3659(99)00015-2.
Kato Y, Onishi H, Machida Y. Biological characteristics of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in mice. J Control Release. 2001;70(3):295–307. doi:10.1016/S0168-3659(00)00356-4.
Yang KW, Li XR, Yang ZL, Li PZ, Wang F, Liu Y. Novel polyion complex micelles for liver-targeted delivery of diammonium glycyrrhizinate: in vitro and in vivo characterization. J Biomed Mater Res A. 2009;88A(1):140–8. doi:10.1002/jbm.a.31866.
Yuan Z-X, Sun X, Gong T, Ding H, Fu Y, Zhang Z-R. Randomly 50% N-acetylated low molecular weight chitosan as a novel renal targeting carrier. J Drug Target. 2007;15(4):269–78. doi:10.1080/10611860701289875.
Yang R, Yang S-G, Shim W-S, Cui F, Cheng G, Kim I-W, Kim D-D, Chung S-J, Shim C-K. Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J Pharm Sci. 2009;98(3):970–84. doi:10.1002/jps.21487.
Joshi N, Shirsath N, Singh A, Joshi KS, Banerjee R. Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: pulmonary compatible and site-specific drug delivery in lung metastases. Sci Rep. 2014;4:7085. doi:10.1038/srep07085.
Ahmad Z, Pandey R, Sharma S, Khuller GK. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci. 2006;48(3):171–6.
Acknowledgement
Abhijeet Joshi acknowledges the INSPIRE Faculty award and fellowship provided by Department of Science and Technology, Government of India. Authors would also like acknowledge financial support from DBT and SERB.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Chaudhari, R., Joshi, A. (2017). Targeted Drug Delivery for Personalized Cure. In: Kaushik, A., Jayant, R., Nair, M. (eds) Advances in Personalized Nanotherapeutics . Springer, Cham. https://doi.org/10.1007/978-3-319-63633-7_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-63633-7_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-63632-0
Online ISBN: 978-3-319-63633-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)